Journal article
Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium
GL Murray, CS Bradshaw, M Bissessor, J Danielewski, SM Garland, JS Jensen, CK Fairley, SN Tabrizi
Emerging Infectious Diseases | CENTERS DISEASE CONTROL | Published : 2017
Abstract
Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure. Macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by the Australia National Health and Medical Research Council program grant APP#1071269 awarded to S.M.G. and C.K.F.